J Updates Cardiovasc Med 2026;14(3):57-67
DOI: 10.32596/jucvm.galenos.2025.2026-11-144

Advances in Mobile Health Strategies for Atrial Fibrillation Detection and Patient Care

Pujan Vyas[1], Emily Klemens[2], Aditya Shaha[3], Rishya Khosla[4], Rahee Patel[5], Mikey Pantoja[6], Katie Rich[7], Amauri Middleton[2], Agilan Saminathan[6], Rohita Muralidaran[6], Kristina Tomanov[3], Sydney Cooper[2], Mikee Kasandra Medrano[6], Paul Nguyen[8]

[1]University of Illinois at Urbana-Champaign College of Liberal Arts & Sciences, Department of Neuroscience, Urbana-Champaign, USA
[2]University of Illinois at Urbana-Champaign College of Liberal Arts & Sciences, Department of Psychology, Urbana-Champaign, USA
[3]University of Illinois at Urbana-Champaign College of Applied Health Sciences, Department of Interdisciplinary Health Sciences, Urbana-Champaign, USA
[4]University of Illinois at Urbana-Champaign The Grainger College of Engineering, Department of Computer Science, Urbana-Champaign, USA
[5]University of Illinois Urbana-Champaign, Urbana-Champaign Gies College of Business, Department of Finance, Urbana-Champaign, USA
[6]University of Illinois Urbana-Champaign College of Liberal Arts & Sciences, Department of Molecular & Cellular Biology, Urbana-Champaign, USA
[7]University of Illinois Urbana-Champaign College of Liberal Arts & Sciences, Department of Chemistry, Urbana-Champaign, USA
[8]Sudden Cardiac-Death Awareness Research Foundation, Urbana-Champaign, USA

Abstract

Atrial fibrillation (AF), a prevalent cardiac arrhythmia, poses significant risks for stroke and other severe complications. Traditional approaches frequently lack accessibility, accuracy, and patient engagement despite advancements in detection and management. The revolutionary effects of mobile health (mHealth) technologies on the treatment of AF are reviewed in this paper. These innovations, which make use of wearable technology, smartphone apps, and sophisticated algorithms, improve patient adherence, increase early detection, and lower healthcare costs. Better results are produced when real-time monitoring and patient-centered tools are incorporated into daily life because they empower people and allow for prompt interventions. However, issues like device restrictions, possible user anxiety, and fair access still exist. This study recognizes areas for additional research and development while highlighting the potential of mHealth to transform the management of AF.

Keywords: Atrial fibrillation, mHealth, medical devices

Address for Correspondence: Emily Klemens, University of Illinois at Urbana-Champaign College of Liberal Arts & Sciences, Department of Psychology, Urbana-Champaign, USA
e-mail: EmilyKlemens12@gmail.com **ORCID:** orcid.org/0009-0005-4168-9988
Received: 04.07.2026 **Accepted:** 21.08.2026 **Publication Date:** 25.09.2026

Cite this article as: Vyas P, Klemens E, Shaha A, et al. Advances in mobile health strategies for atrial fibrillation detection and patient care. J Updates Cardiovasc Med. 2026;14(3):57-67

DOI: 10.32596/jucvm.galenos.2025.2026-11-144

Introduction

Atrial fibrillation (AF) is a common type of arrhythmia where the heart beats irregularly and too fast, leading to reduced blood flow to the body. The sinus node in the heart sends signals to regulate heart contractions, but in individuals with AF, these signals are chaotic and untimely due to electrical misfirings[(1)]. These misfirings result in trembling in the atriums–the upper chambers of the heart–which limits the efficiency of the heart. AF is characterized by the atriums beating out of rhythm with the heart's ventricles, typically from electrical misfiring. AF symptoms include tachycardia (120-160 bpm), light-headedness, shortness of breath, chest pain, fatigue, high blood pressure, dizziness, and weakness[(1)]. While this condition is not directly life-threatening, it can lead to higher risks of stroke, myocardial infarction, chronic kidney disease, dementia, and cancer[(2)]. However, almost one-third of all patients with AF are asymptomatic, resulting in a lack of treatment to prevent these more life-threatening side effects of AF from appearing[(2)].

There are four main types of AF: paroxysmal, persistent, long-standing persistent, and permanent AF. With paroxysmal AF, symptoms last from a few minutes to a few hours and are relatively low risk. The heart rhythm is inconsistent for longer periods with persistent AF, and patients with long-standing persistent AF exhibit symptoms that last over twelve months. In cases of persistent AF, medical procedures may be required to correct the arrhythmia in these instances. Permanent AF, the most severe type of AF, results when the patient's heart rhythm cannot be reset, and medications are required to prevent blood clot formation[(1)]. Risk factors for developing AF include age, body mass index, hypertension, height, diabetes mellitus, obstructive sleep apnea, past myocardial infarction, heart failure, smoking, and genetic predisposition (Information, et al. 2017). AF affects 5% of the adult population or approximately 10.5 million adults, so developing new and accessible treatment and prevention plans is essential to improving lifestyles for affected individuals throughout the world[(3)].

Mobile health (mHealth) technology has improved the rapidity of AF diagnosis and patient engagement due to advancements in technology such as the modern use of smartphones and watches as electrocardiography (ECG) monitors. Research shows that mHealth interventions improve outcomes compared to standard care. A PubMed study testing the facilitation of smartwatches with AF detection explains, "...13 of 14 studies support the effectiveness of mHealth interventions compared with standard care" and "smartphone-connectable ECG devices provide patients with the ability to document a rhythm disturbance more easily than with standard care, which may increase empowerment and engagement about their illness"[(4)]. The accessibility and ease of self-monitoring directly relate to potentially reducing the need for emergency room visits and lowering mortality rates. Adding these devices to AF management may improve outcomes through early stroke prevention and fewer hospital visits for AF patients. In a study from the University of North Carolina, wearables directly correspond with continuous monitors, resulting in timely care[(3)]. This increased awareness of individual health caused by monitoring devices directly helped with early detection of potentially drastic health consequences and visits to the emergency room. These studies indicate the benefits that mHealth technology is bestowing upon patients throughout the world. This analysis will convey how the field of mHealth advances as new research highlights the benefits of wearable technology and mobile applications in detecting AF earlier.

Materials and Methods

This comprehensive review synthesizes current research and technological developments in AF detection, patient engagement, and healthcare outcomes. The methodology consisted of three primary components: literature review, technology assessment, and outcomes analysis.

Literature Review

We conducted a systematic review of peer-reviewed articles, clinical studies, and medical research papers published between 2014 and 2024. Key databases searched included PubMed, NCBI, and AHA Journals. Studies were included if they focused on AF detection methods, patient engagement strategies, or outcome measurements. Articles were excluded if they were published before 2014 or focused solely on pharmaceutical interventions.

Technology Assessment

The evaluation of AF detection technologies involved analyzing multiple device categories:

1. Traditional monitoring devices (12-lead ECG, Holter monitors)
2. Wearable technologies (smartwatches, fitness trackers)
3. Mobile applications (FibriCheck, CardiacRhythm, Preventicus, PULSESMART)
4. Implantable devices
5. Novel prototypes (Bitalino ECG sensor systems)

For each technology category, we assessed:

- Detection accuracy (sensitivity and specificity rates)
- Data collection duration capabilities
- Real-world performance metrics
- User accessibility and engagement factors
- Integration with healthcare systems

Outcomes Analysis

Patient outcomes were evaluated through multiple metrics:

1. Clinical outcomes:

○ AF detection rates

○ Time to medical intervention

○ Emergency room visit frequency

○ Hospitalization rates

2. Patient engagement metrics:

○ Adherence to monitoring protocols such as how consistently patients follow prescribed monitoring regimens, such as wearing a heart monitor daily or checking blood pressure at home.

○ Treatment compliance

○ Quality of life measurements referring to the patient's overall well-being, considering both physical and mental health.

3. Economic impact:

○ Healthcare resource utilization

○ Cost-effectiveness of various detection methods

○ Impact on different socioeconomic groups

Data Synthesis

The collected data was synthesized to identify:

1. Comparative effectiveness of different detection technologies
2. Barriers to implementation and adoption
3. Impact on patient outcomes and healthcare delivery
4. Economic implications of various detection strategies
5. Areas requiring further research or development

This methodological approach enabled a comprehensive assessment of current AF detection technologies, their implementation in healthcare settings, and their impact on patient outcomes and healthcare delivery systems.

Device Accuracy and Detection Rates

Understanding the accuracy and reliability of different detection devices is a crucial factor in selecting the most appropriate device for monitoring AF. Conventionally, the Holter monitor has been used as the primary ECG device for detecting AF in patients(5). However, the rise of more wearable, less-cumbersome technology provides more options for physicians and patients to select from(6).

It is necessary that this new technology is compared to more established AF monitoring devices to ensure that these new devices can accurately detect AF in patients.

Numerous studies have tested the accuracy of using electrocardiogram patches or Holter monitors to detect AF. A study from the Ajou University School of Medicine utilized a new patch ECG device called MobiCARE-MC100 on AF patients undergoing cardiac surgery and compared its effectiveness in detecting AF detection to the conventional Holter device[6]. Patients wore the patch ECG as well as the Holter monitor for 24 hours to determine whether both devices detected the same number of AF events. The results of the study demonstrated that both devices detected the exact same number of AF events, indicating a similar level of accuracy with the new MobiCARE-MC100 device[6]. This study provides backing for new ECG devices that can be used to detect AF and allow for patients to monitor AF with ease and comfort, as the patch ECG requires minimal maintenance and is easy to apply. An additional study by the Seoul National University Hospital measured the accuracy of AF detection using the conventional Holter test and with an adhesive patch-type device[7]. Similar to the study by Ajou University School of Medicine, this study measured the number of AF detection events in both devices for 24 hours, measuring the same number of events in patients[7]. Both studies indicate that adhesive patches can be used to detect AF in patients with the same accuracy rates as a Holter test[6,7]. Additionally, the ECG patches such as the MobiCARE-MC100 are more discrete and thus easier to wear for extended periods of time without uncomfortability or hindrance, which may result in patients being more willing to undergo the testing period[6].

These studies also measured the effects of patch testing over longer periods of time. While the Holter monitor is typically only administered for 24 hours, the ease and minimal invasiveness of patch testing can allow for the testing to occur for longer periods of time, thus increasing the number of AF events that could be detected. A study by Scripps Translational Science Institute in California studied the effects of a 14-day patch ECG in AF detection compared to the 24-hour Holter monitor test. The results of the study demonstrated the patch monitor detected significantly more AF events than the Holter monitor, with 96 arrhythmia events detected compared to 61 ($p<0.001$)[8]. These findings are supported by the studies from the Ajou University School of Medicine and Seoul National University Hospital, as these studies also tested the effects of wearing the adhesive patch ECG for 72 hours[7]. The Ajou University School of Medicine detected an increase in AF events from 9% to 38% within 48 hours of the 72 hour testing period (https://pubmed.ncbi.nlm.nih.gov/38419583/). Seoul National University Hospital found that wearing the patch ECG for 72 hours increased the detection rate of AF by 1.5-fold, and the detection rate of paroxysmal AF increased with the patch ECG by 2.2-fold [7]. These studies indicate that the ability for patch ECGs to be worn for extended periods of time shows significant improvement in the detection of AF events among patients[8]. This discovery is revolutionary to mHealth field, as wearing patch ECGs could allow for detection of AF in early presenting individuals to allow for immediate treatment and improve their duration of life. While patch testing may require a more extended duration of application, the benefits outweigh the drawbacks as the ability to detect AF more accurately can allow for faster diagnosis of AF and treatment of the patient. Future testing should consider the effects of even longer patch testing to determine whether an even more extended time period could reveal more AF events and lead to further beneficial diagnoses for patients.

While a variety of new devices have been developed, there remain several limitations in their detection rates and practicality, including their monitoring windows, false positives, and recording dependence. In most studies conducted with monitors, researchers report a range of patient participation from 64% to 80% of patients consistently complying with device usage[9,10]. The table below indicates the rates of wear compliance across several studies testing device accuracy with AF detection. Due to the varying compliance of patients wearing recording technology, there may be a higher number of AF events not recorded. Another limitation includes the false positive rate of AF detection. Several studies indicated patients received false alerts due to irregular pulse notifications or misinterpreted ECG data[11,12]. Advances are still being made today to rectify these errors and eliminate the frequency of false errors. Detection rates of various recording devices can be seen in Table 1 below. Devices will shorter monitoring windows such as the short-term chest monitors and handheld single-lead ECG may result in a decreased AF detection rate due to the finite window of detection time. In part, the accuracy of mobile devices is dependent on the diligence of the patient. The handheld single-lead ECG depends on the frequency of the user to record AF events, therefore attributing to its lower detection rate. Overall, these ECG devices are accurate to a fault, with several limitations remaining in their operating structure, patient compliance, and detection rates[9,11,13]. Device accuracy rates shown comparatively in Graph 1, with comparative accuracy, efficiency, and accessibility data shown in Table 1.



Graph 1. The graph above indicates the sensitivity, accuracy, and specificity of various mobile health devices in regards to atrial fibrillation detection[5-13]
ECG: Electrocardiogram

Table 1. The wear compliance and detection rates of different types of atrial fibrillation recording devices is shown above[9-12]

	Wear compliance	AF detection rates
Short-term chest monitors	67%	70%
Smartwatches (PPG)	35%	34%
Handheld single-lead ECG	74%	79%
Insertable/implantable loop recorders	100%	52%

ECG: Electrocardiogram, PPG: Photoplethysmography, AF: Atrial fibrillation

Impact on Timely Patient Interaction

The development of wearable technology such as wristwatches, chest bands, and implantable ECGs has facilitated the transition of AF treatment from in-hospital procedures to outpatient prevention[4]. With new mobile applications such as FibriCheck, CardiacRhythm, Preventicus, and PULSESMART, wearable devices can detect arrhythmias and symptoms of AF, alerting the patient via the app when signs occur. The devices conduct an electrocardiogram, or ECG, at regular intervals and can detect AF in as little as thirty seconds with a single lead ECG[14]. Detection of AF with this single-lead ECG can prompt more in-depth screening with 12-lead ECGs to further confirm an AF diagnosis[15]. Due to this new technology, patients can become aware of their symptoms and seek medical attention more rapidly, resulting in a decreased risk of AF developing into cardiac arrest or stroke[14].

Traditional ECG testing is expensive and requires patients to visit a clinical setting for monitoring, which makes it impracticable for frequent tracking and daily, personal use. This reliance on in-clinic testing can delay diagnosis, especially for individuals without immediate access to healthcare facilities. Moreover, the need for trained professionals to operate the ECGs is a burden for healthcare providers because resources like time, staff, and equipment are heavily allocated to ECG testing, leaving less capacity for other patient needs[4].

A new prototype has been developed to create a low-cost, user-friendly device for early detection of AF in home settings, allowing for timely intervention and emergency medical services (EMS). This prototype uses a Bitalino ECG sensor, which is a simple and affordable device that allows for the real-time collection of high-quality heart signals, making it ideal for portable health monitoring. The prototype is integrated with an Arduino microcontroller, a system that processes ECG data, runs the arrhythmia detection algorithm, and identifies abnormalities such as high beats per minute (BPM) or irregular R-R intervals. Healthy ECG data was collected via self-testing, and AF data came from the Massachusetts Institute of Technology-Beth Israel Hospital AF database. The AF detection algorithm identifies high BPM (>100) and inconsistent R-R intervals (outside 0.6-1.2s), achieving 88% accuracy, which improved with a lower BPM threshold of 90. This device can help patients seek timely EMS support, reducing risks associated with delayed treatment. Future improvements for the device include more advanced microcontrollers, better sensors, and larger-scale testing to improve reliability and accessibility for a larger population[16]. Additionally, as telehealth becomes more prevalent today, physicians can access patient data from these mobile applications to receive a more extensive overview of the patient's condition and provide necessary treatment. Another benefit of mHealth applications is to promote early screening for AF, allowing patients to receive a diagnosis earlier and enabling them to take preventative measures before symptoms worsen[14].

New evidence highlights the importance of implementing a simple, scalable, and pragmatic population-based pathway for AF screening. Systematic screening is recommended for individuals aged 65 and over. Consumer-led screening can be an entry point into this systematic approach but requires careful evaluation of its diagnostic implications and healthcare resource demands. With an emphasis on quantifying the claimed benefits of mobile technologies, the authors carried out a systematic review to look at the data pertaining to the influence of mobile handheld technology on hospital physicians' work practices and patient care. Thirteen studies were found by the authors to show how personal digital assistants (PDAs) can improve data management and accessibility, error prevention, and rapid response. PDA use is most beneficial in situations where time is of the essence and prompt action is essential. This technology can facilitate immediate action by physicians to inform patients of health concerns or a necessary adjustment to ongoing treatments in response to this mobile data. In one instance, a hospital that switched to this method of data transmission experienced a 50% decrease in the number of patients admitted to the hospital via emergency transportation for coronary occlusions, which is an artery blockage that can be exacerbated by having AF[13].

Developing effective AF surveillance strategies remains challenging, with limited evidence supporting their utility for broad population use. However, the integration of mHealth technologies and wearable devices has revolutionized AF detection and management, enabling earlier diagnosis, timely interventions, and more efficient use of healthcare resources, ultimately reducing the risks of severe complications and improving patient outcomes.

Patient Outcomes

Advancements in healthcare are not only about improving clinical outcomes as they also emphasize enhancing patient's quality of life. In recent years, mHealth technologies have emerged as promising tools in managing chronic conditions like AF. mHealth technologies in treating AF have even gone beyond simple treatment; one study concluded an improvement in quality-of-life questionnaire scores after 6 months of using myAlgos, an app for symptom and treatment management[2]. The app offers frequent reminders as well as physician-approved laymen information. Its usability is targeted at laypeople, improving patient outcomes in high percentages of the population.

Adherence to treatment plans is critical in achieving longevity of positive health outcomes.

However, it is reported that as many as one-third to two-thirds of patients struggle with adhering to their treatments that included physiotherapy[17]. This struggle could be due to factors such as lack of motivation, forgetfulness, or just having a demanding lifestyle. A study examining the impact of a mHealth app on physical health treatments found that apps and wearable technology significantly improve a patient's ability to stick to their treatments by providing reminders, tracking progress over some time, and being able to communicate with healthcare providers more efficiently[17]. The article by Greenstein et al.[17] also showed that patients using the Kanvas app were more likely to keep their follow-up appointments.

15.25 to 13.82 of physician-discharged patients and 7.79 to 4.58 of self-discharged patients kept their appointments, again, the Kanvas app patients kept their appointments more frequently[17]. This trend speaks to enhanced patient outcomes, with those who are more likely to keep their appointments more likely to receive better health outcomes overall. Having wearable technology that sends alerts like high heart rate or abnormal ECG results can help one stay aware of issues and set reminders to take prescribed treatments, attend appointments, and maintain a healthy lifestyle. Some apps that have these features that lead to timely EMS contact are FibriCHeck, CardiacRhythm, etc. These features can help patients monitor their condition closely and ensure AF symptoms are caught beforehand. Furthermore, apps that are tailored for AF management can offer educational resources to empower patients on the importance of lifestyle changes like diet, exercise, and stress management.

mHealth technologies have been shown to have economic benefits, particularly due to their positive impact on treating AF. One research paper that used a retrospective, observational, single-center study method analyzed the cost-effectiveness of mHealth technologies and treating AF and examined the outcomes of standard treatment and treatment supplemented with mHealth. The study found that reduced incidences of various subsequent AF-related outcomes such as stroke, rehospitalization, or even death, led to overall reduced costs[18]. Another descriptive observational study relating mHealth technology to economic disparity shows that there is a significantly high percentage of interest in participation within low-income communities in having access to mHealth technologies. This positive uptake can be attributed to mHealth applications that are sensitive to user needs and a diverse population. By considering the visual and linguistic design of mHealth applications to better overcome mobile application fluency, the divide in healthcare fluency and disparities can decrease with diverse economic groups[19].

AF is a significant public health challenge because of its broad impact on the patient and healthcare systems. Patients who have AF face a higher risk of stroke, heart failure, and mortality which contributes to heightened healthcare resources used and economic burdens[15]. The higher risk of severe complications such as stroke and heart failure not only decrease the patient's quality of life but can strain healthcare infrastructure. These outcomes emphasize the need for early detection and preventative measures to steer away from major heart issues and improve patient outcomes. The Global Burden of Disease Study reported that in 2019 alone, AF was the cause of 315,000 deaths and these outcomes disproportionately affect populations with limited access to preventative care and lower socio-demographic backgrounds. Addressing changeable factors, like hypertension and obesity through public health projects like affordable screenings, patient education, and equitable access to healthcare can reduce AF's global impact[15].

Despite the plethora of potential benefits that mHealth presents in treating AF and managing symptoms, the potential pitfalls of this methodology are present. One limitation noted by a study from a trial utilizing smartwatches and smartphones found that most participants recorded a surprisingly low number of AF symptoms due to needing to recharge the devices[20]. Additionally, there have been concerns those technologies with a heightened awareness of little fluctuations in the heart's activity increase anxiety among the wearers. This may lead to unnecessary hospital visits or unneeded medical interventions. Despite the concerns, these connections do not have solidified studies to support such claims and should not discourage the use of these technologies. New technologies have even begun to be implemented in the treatment of this disease, aiming to remedy these limitations and provide even better care to those with AF.

Innovation in Detection Technologies

For years, the primary method of diagnosing AF and other causes of sudden cardiac death has been through the traditional 12-lead ECG, or more recently, through the use of wearable device technologies. The 12-lead ECG has been the standout method for detection up until recent years because it makes use of electrodes to provide a multi-dimensional view of the heart's activity. The use of the 12-lead ECG is considered "traditional" because the noninvasive imaging test allows for quick diagnosis on-site as it relates to coronary artery disease, myocardial infarction, or other episodes(19). While this method has proven effective and essential to the growing knowledge surrounding sudden cardiac death, it can be time-consuming, requires preparation beforehand, and is not a constant detection method.

A specific interest for technologies aiming to detect AF and/or similar episodes is for said technology to be constant, easily monitorable, and most importantly quickly alert the patient of a risk in their condition. For this reason, wearable device technologies have gained popularity in recent years because they allow for a similar security that the 12-lead ECG provides to become portable and therefore provide a persistent source of monitoring, with the main goal being to recognize complications in real-time. One of the earliest and most well-known wearable detection technologies is FitBit, which makes use of optical photoplethysmography (PPG) sensors to measure pulse rate(21). Since the creation of Fitbit, PPG has been used and refined as a technology through other brands as well as the development of mobile apps to accompany wearable devices. The development and function of wearable device technologies have also greatly been aided by artificial intelligence algorithms. The integration of AI algorithms has increased the success rates of both prevention and treatment significantly when it comes to sudden cardiac death, with automation of monitoring services and alert systems becoming an important focus. AI has helped improve patient prognosis through earlier detection and a notable improvement in accuracy through its use in both traditional technology such as ECGs and wearable devices, or even more specified and advanced modern technology that gears their focus towards cardiac electrophysiology, the physiological function of the electrical conduction system of the heart. Innovative AI-powered personal devices have achieved a near clinical-grade accuracy in detecting AF. For example, the six-lead KardiaMobile 6L smartphone ECG showed an approximate 99% sensitivity and an approximate 91% specificity of AF for studies testing validation(9). Its single-lead precursor similarly showed high diagnostic accuracy, with sensitivity ranging from 92% to 99% and specificity ranging from 92% to 99%(22,23). The KardiaMobile devices are also relatively affordable, with the single-lead product priced at around 83 euros, which is equivalent to about $110, and the six-lead model launches at approximately $149.23,30 Another product is the Apple Watch Series 9, which has on device AI algorithms that use both ECG and PPG sensors. These sensors detect AF with about 95% sensitivity and 95% specificity(23,24). In the Apple Heart Study, an irregular pulse notification from an earlier model of an Apple Watch had a positive predictive value of approximately 84% for AF(25). Apple's latest watch being the series 11, retails for $399 excluding taxes. Data for comparative pricing shown in Table 2

Detection technology as a whole has increasingly grown over the past decade, with notable feats in application to mobile devices, smartwatches, and everyday technology that make crucial information about one's cardiac health easily accessible and most importantly, capable of direct analysis. Two examples of current successful monitoring technology include the HiCardi and MobiCARE devices, which have proven that a new era of cardiological health crisis prevention is quickly approaching–one in which accuracy, efficiency, and accessibility play a role in transforming the prognosis associated with typical causes of sudden cardiac death (see Table 1 below). Sensor technology has also greatly improved through the efficient use of machine learning which has led to the ability for

Table 2. The above table indicates the cost, charge time, and recording time of various mobile health devices in detecting atrial fibrillation[22-25]

	Cost	(Max) charge time	Recording time
Traditional 12-lead ECG	\$178-\$600	N/A	10 seconds
HiCardi	\$280-\$730	1.5	72 hours
MobiCARE-MC100	\$360-\$1800	1.5	72 hours
Fitbit (PPG)	\$130-\$300	1-2	6-10 days
24-hour holter monitor	\$150-\$600	4	24 hours

ECG: Electrocardiogram, PPG: Photoplethysmography

even minute body-language detection mechanisms to play a role in the prevention and treatment of cardiac crises. While current technology applied to cardiological crises has improved greatly, we aim to analyze the growth and projection of these current technological feats as they build off of traditional interventions, but with greater automation and efficiency, with certain criteria in mind such as patient comfort and accessibility, provider education, trust, and real-time reliability. With major improvements to wearable devices such as more compact and lightweight designs, wearability has increased, allowing patients to monitor their heart health with ease continuously. These developments contribute to the seamless integration of technology into everyday life, ensuring that critical health insights are available and reliable, improving not only the overall monitoring of cardiac health but also patient quality of life.

Summary

This review highlights the transformative role of mHealth technologies in AF management, emphasizing advancements in device accuracy, timely patient interaction, patient outcomes, and detection innovation. Devices such as wearable technologies, smartphone-connected ECGs, and implantable cardiac monitors demonstrate high sensitivity and specificity for AF detection, with smartphone ECG devices like Kardia achieving sensitivity rates of 98.5% and specificity rates of 91.4%[24]. These technologies surpass traditional tools like Holter monitors in accessibility and ease of use, but limitations such as short monitoring durations and the risk of false positives highlight the need for optimization[26].

In parallel, mHealth tools have revolutionized timely patient interactions, enabling rapid identification of AF episodes through wearable devices and mobile apps such as FibriCheck and CardiacRhythm. For instance, prototypes like the Bitalino ECG sensor integrated with Arduino microcontrollers have achieved promising detection accuracy, offering affordable solutions for home-based monitoring[16]. Despite these advances, challenges remain, including device recharging needs and user anxiety stemming from frequent alerts[20].

Beyond detection, mHealth technologies significantly improve patient outcomes by enhancing treatment adherence and promoting engagement. Features such as reminders and real-time monitoring have demonstrated success in reducing hospitalizations and increasing appointment attendance rates[17]. Importantly, these tools address healthcare disparities by providing cost-effective options for underserved populations, with studies showing high interest and usability among low-income groups[19]. However, economic barriers and disparities in technology access highlight the need for affordable and inclusive solutions to ensure equitable adoption.

Innovations in detection technologies further solidify mHealth's role in AF management. Developments in PPG and artificial intelligence (AI) have improved the accuracy and efficiency of wearable devices, with AI enabling predictive analytics and personalized care strategies[21]. Lightweight and compact designs enhance device usability, while real-time health insights empower patients to take a proactive role in their care.

These advances pave the way for systematic population-wide screening, particularly among high-risk groups, to reduce the global burden of AF.

Conclusion

A paradigm shift in AF detection, treatment, and patient engagement has been brought about by the incorporation of mHealth technologies. This thorough analysis conveys how improvements in wearable technology, smartphone apps, and creative detection tools greatly improve patient outcomes and early AF detection. With their high sensitivity and specificity in detecting AF, technologies like implantable cardiac monitors, smartphone-connected ECGs like Kardia, and wearables based on PPG have reduced the need for invasive, in-clinic procedures while facilitating prompt intervention. Additionally, these tools give patients the ability to actively monitor their health, which improves treatment plan adherence and lowers the need for emergency medical care.

Mobile applications and wearable technologies also enhance accessibility to AF management, with features that encourage preventive care and lifestyle changes. However, challenges persist, including device limitations such as short monitoring durations, the risk of false positives, and barriers related to cost and user education. Notably, while the economic benefits of these technologies are evident, their adoption must consider the needs of low-income populations and those with limited healthcare access.

Emerging technologies, such as prototypes leveraging Bitalino ECG sensors and Arduino microcontrollers, indicate a promising future for affordable and scalable AF detection. These innovations highlight the potential for systematic population-wide screening, especially in high-risk groups. Despite concerns like anxiety induced by continuous monitoring and device recharging issues, the overarching benefits of mHealth in AF care outweigh its limitations.

The results highlight how important it is to conduct additional investigations in order to improve device performance, address inequalities in technology adoption, and smoothly incorporate these tools into healthcare systems. mHealth technologies have the potential to transform AF care by emphasizing patient comfort, real-time dependability, and equitable access, ultimately lessening the burden of the condition on both individuals and healthcare systems.

To encourage broader adoption, future research should concentrate on improving detection devices' efficiency and accuracy, lengthening their monitoring periods, and making them more user-friendly. It will also be crucial to address inequalities in access to mHealth technologies, especially by creating affordable devices and educational materials specifically for marginalized communities[20]. The long-term clinical and financial effects of these technologies, including their potential to lower AF-related complications and enhance healthcare delivery, require more investigation. Furthermore, investigating the incorporation of artificial intelligence into wearable technology may open the door to customized treatment plans and predictive analytics. In order to counteract the increasing burden of AF, the future of mHealth in AF management promises to provide creative, fair, and patient-centered solutions by filling in these gaps.

Ethics

Acknowledgement

Thank you to Sudden Cardiac-death Awareness and Research Foundation for providing peer review and instruction regarding the meta-analysis process. Thank you to the University of Illinois at Urbana-Champaign for accepting our meta-analysis to the Undergraduate Research Symposium. No financial support was provided in the writing of this manuscript.

Footnotes

Authorship Contributions

Concept: Vyas P, Design: Vyas P, Analysis and/or Interpretation: Vyas P, Klemens E, Shaha A, Khosla R, Patel R, Pantoja M, Rich K, Middleton A, Saminathan A, Muralidaran R, Tomanov K, Cooper S, Medrano MK, Nguyen P, Writing: Vyas P, Klemens E, Shaha A, Khosla R, Patel R, Pantoja M., Rich K, Middleton A, Saminathan A, Muralidaran R, Tomanov K, Cooper S, Medrano MK, Nguyen P.

Conflict of Interest: The authors declare no conflicts of interest concerning the authorship or publication of this article.

Financial Disclosure: This research received no specific grants from any funding agency in the commercial or not-for-profit sectors.

References

1. Mayo Clinic. (n.d.). Atrial fibrillation: Symptoms and causes. Available from: https://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/symptoms-causes/syc-20350624
2. Kornej J, Börschel CS, Benjamin EJ, et al. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights. Circulation Research. 2020;127:4-20.
3. Fernandez, E. How many people have A-fib? Three times more than we thought. University of California, San Francisco. Available from: https://www.ucsf.edu/news/2024/09/428416/how-many-people-have-fib-three-times-more-we-thought
4. Gibson CM, Steinhubl SR, Lakkireddy D, et al. Does early detection of atrial fibrillation reduce the risk of thromboembolic events? Rationale and design of the Heartline study. Am Heart J. 2023;259:30-41.
5. Brik T, Lucassen WAM, Harskamp RE, et al. Personalized approach using wearable technology for early detection of atrial fibrillation in high-risk primary care patients (PATCH-AF): study protocol for a cluster randomized controlled trial. Am Heart J. 2022:254:172-82.
6. Hyun S, Lee S, Hong YS, et al. Evaluation of the diagnostic performance and efficacy of wearable electrocardiogram monitoring for arrhythmia detection after cardiac surgery. J Chest Surg. 2024;57:205-12.
7. Kwon S, Lee SR, Choi EK, et al. Comparison between the 24-hour Holter test and 72-hour single-lead electrocardiogram monitoring with an adhesive patch-type device for atrial fibrillation detection: prospective cohort study. J Med Internet Res. 2022;24:e37970.
8. Barrett PM, Komatireddy R, Haaser S, et al. Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch electrocardiographic monitoring. Am J Med. 2024;127:95.e11-95.e17.
9. Halcox JPJ, Wareham K, Cardew A, et al. Assessment of remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: the REHEARSE-AF study. Circulation. 2017;136:1784-94.
10. Perez MV, Mahaffey KW, Hedlin H, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med. 2019;381:1909-17.
11. Ip J, Jaffe B, Castellani M, et al. Accuracy of arrhythmia detection in implantable cardiac monitors: a prospective randomized clinical trial comparing Reveal LINQ and Confirm Rx. Pacing and Clinical Electrophysiology. 2020;43:1344-50.
12. Ko JS, Jeong HK. Screening for atrial fibrillation using a single lead ECG monitoring device. Chonnam Med J. 2021;57:191-6.
13. Prgomet M, Georgiou A, Westbrook JI. The impact of mobile handheld technology on hospital physicians' work practices and patient care: a systematic review. J Am Med Inform Assoc. 2019;16:792-801.
14. Bonini N, Vitolo M, Imberti JF, et al. Mobile health technology in atrial fibrillation. Expert Rev Med Devices. 2022;19:327-40.
15. Jiao M, Liu C, Liu Y, et al. Estimates of the global, regional, and national burden of atrial fibrillation in older adults from 1990 to 2019: insights from the Global Burden of Disease study 2019. Front Public Health. 2023;11:1137230.
16. Ahmed N, Zhu Y. Early detection of atrial fibrillation based on ECG signals. Bioengineering (Basel). 2020;7:16.
17. Greenstein J, Topp R, Etnoyer-Slaski J, et al. Effect of a mobile health app on adherence to physical health treatment: retrospective analysis. JMIR Rehabil Assist Technol. 2021;8:e31213.
18. Luo X, Xu W, Ming WK, et al. Cost-Effectiveness of mobile health-based integrated care for atrial fibrillation: model development and data analysis. J Med Internet Res. 2022;24:e29408.
19. Li DL, Kronenberg MW. Myocardial perfusion and viability imaging in coronary artery disease: clinical value in diagnosis, prognosis, and therapeutic guidance. Am J Med. 2021;134:968-75.
20. Wouters F, Gruwez H, Vranken J, et al. The potential and limitations of mobile health and insertable cardiac monitors in the detection of atrial fibrillation in cryptogenic stroke patients: preliminary results from the REMOTE trial. Front Cardiovasc Med. 2022;9:848914.
21. Lubitz SA, Faranesh AZ, Selvaggi C, et al. Detection of atrial fibrillation in a large population using wearable devices: the fitbit heart study. Circulation. 2022;146:1415-24.
22. Turnbull S, Garikapati K, Bennett RG, et al. Accuracy of a single-lead ECG device for diagnosis of cardiac arrhythmias compared against cardiac electrophysiology study. Heart Lung Circ. 2024;33:1465-74.
23. Shahid S, Iqbal M, Saeed H, et al. Diagnostic accuracy of apple watch electrocardiogram for atrial fibrillation: a systematic review and meta-analysis. JACC Adv. 2025;4:101538.
24. Gibson CM, Steinhubl S, Lakkireddy D, et al. Does early detection of atrial fibrillation reduce the risk of thromboembolic events? Rationale and design of the Heartline study. Am Heart J. 2023;259:30-41.
25. Hamad AKS. New technologies for detection and management of atrial fibrillation. J Saudi Heart Assoc. 2021;33:169-76.
26. Ciconte G, Giacopelli D, Pappone C. The role of implantable cardiac monitors in atrial fibrillation management. N Engl J Med. 2017;10:1590.